The drug manufacturer Stada made a profit of EUR 20.5 million in the third quarter after a large loss of EUR 62.4 million a year earlier.
This is an important step for the Group in the Hessian town of Bad Vilbel, following the expansion to Eastern Europe where Stada’s sales rose in the first three quarters of the current fiscal year by 15 percent to EUR 384.5 million.
Consolidated sales increased by 6 percent to eur 1,332.5 billion. Sales of the core segment generics thereby pointed to a sales increase of 2 percent to EUR 872.4 million. Generics thus contributed during the period 65.5 percent of the Group’s sales. Own brand products produced revenue growth of 25 percent to EUR 437.9 million.
[ilink url=“http://www.stada.de/stada/presse/presse_adhoc/AktuelleMeldungen/details.asp?pid=847″] Link zur Quelle (Stada)[/ilink]